Press releaseGlobe Newswire
NKGen Biotech
NKGN · OTC
$0.011+$0.00 (+0.00%)TodayMarket closed ·
Prev close $0.011
Latest news
- Press releaseGlobe Newswire
NKGen Biotech to Present on Potential of Troculeucel in Neurodegenerative Diseases at Biologics Manufacturing Korea 2026
- Press releaseGlobe Newswire
NKGen Biotech to Present at the 2026 BIOCHINA Global Forum on Troculeucel’s Potential in Alzheimer’s Disease and Other Neurodegenerative Conditions
- Press releasePRNewswire
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company
- Press releaseGlobe Newswire
NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer's and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit
- Press releaseGlobe Newswire
NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer's Disease at AD/PD 2026™
- Press releaseGlobe Newswire
NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer's Disease at AD/PD™ 2026
- Press releaseGlobe Newswire
NKGen Biotech Provides Clarification on Quotation Display and Trading Status on the OTC Expert Market
- Press releaseGlobe Newswire
NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the XXVII World Congress of Neurology
- Press releaseGlobe Newswire
NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the 3rd China Great Bay Cell and Gene Therapy Forum
- Press releaseGlobe Newswire
NKGen Biotech Administers First Dose of Troculeucel to Alzheimer's Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting Therapy
- Press releaseGlobe Newswire
NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
- Press releaseGlobe Newswire
NKGen Biotech To Present on the Use of Troculeucel for Alzheimer's and Parkinson's Disease at the 7th China International Biotechnology Conference & Exhibition
- Press releaseGlobe Newswire
NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025)
- Press releaseGlobe Newswire
NKGen Biotech To Present on Potential of Troculeucel for the Treatment of Neurodegenerative Diseases at the 13th Annual Alzheimer's & Parkinson's Drug Development Summit
- Press releaseGlobe Newswire
NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer's Disease with AdventHealth Orlando as First East Coast Site
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- NewsAvi Kapoor
Why Spirit Airlines Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket
- NewsAvi Kapoor
Dow Falls Over 100 Points; Netflix Posts Upbeat Results
- NewsAvi Kapoor
Why Intuitive Surgical Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
- NewsAvi Kapoor
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
- NewsAvi Kapoor
Why Tellurian Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket
- NewsAvi Kapoor
Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- NewsHenry Khederian
Why NKGen Biotech (NKGN) Stock Is Skyrocketing
- News
Market-Moving News for July 18th
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.